Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04943900
Recruitment Status : Not yet recruiting
First Posted : June 29, 2021
Last Update Posted : June 29, 2021
Sponsor:
Information provided by (Responsible Party):
Bristol-Myers Squibb

Brief Summary:
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.

Condition or disease Intervention/treatment Phase
Advanced Solid Tumors Drug: BMS-986416 Drug: Nivolumab Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 134 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of BMS-986416 Alone and in Combination With Nivolumab in Select Solid Tumors
Estimated Study Start Date : June 30, 2021
Estimated Primary Completion Date : November 13, 2023
Estimated Study Completion Date : November 14, 2023

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arm Intervention/treatment
Experimental: Part 1A: Monotherapy (BMS-986416) Drug: BMS-986416
Specified dose on specified days

Experimental: Part 1B: Combination Therapy (BMS-986416 + Nivolumab) Drug: BMS-986416
Specified dose on specified days

Drug: Nivolumab
Specified dose on specified days
Other Names:
  • BMS-936558
  • Opdivo




Primary Outcome Measures :
  1. Incidence of Adverse Events (AEs) [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  2. Incidence of Serious Adverse Events (SAEs) [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  3. Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  4. Incidence of AEs leading to discontinuation [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  5. Incidence of AEs leading to death [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  6. Protocol-defined maximum tolerated dose (MTD) or maximum administered dose (MAAD) [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]

Secondary Outcome Measures :
  1. Maximum observed serum concentration (Cmax) of BMS-986416 [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  2. Time of maximum observed serum concentration (Tmax) of BMS-986416 [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  3. Trough observed serum concentration (Ctrough) of BMS-986416 [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
  4. Overall Response Rate (ORR) using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) per Investigator assessment [ Time Frame: Up to 2 years ]
  5. Duration of Response (DOR) using RECIST 1.1 per Investigator assessment [ Time Frame: Up to 2 years ]
  6. Incidence of clinically significant changes in ECG parameters: QTcF [ Time Frame: Up to 100 days after the last treatment of study intervention(s) ]
    QTcF = Corrected QT interval using the Fridericia formula. QT interval is the time from the start of the Q wave to the end of the T wave



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit:

www.BMSStudyConnect.com

Inclusion Criteria:

  • Participants with histologically or cytologically confirmed locally advanced unresectable, metastatic, or recurrent select solid tumor
  • Eligible tumor types Non-small cell lung cancer (NSCLC), Urothelial carcinoma (UC), Squamous cell carcinoma of the head and neck (SCCHN), Hepatocellular carcinoma (HCC), Microsatellite-stable colorectal carcinoma (MSS CRC), or Pancreatic ductal adenocarcinoma (PDAC)
  • Resistant/refractory to or intolerant of existing standard therapies known to provide clinical benefit
  • Measurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v 1.1)
  • Disease amenable to serial biopsy

Exclusion Criteria:

  • Uncontrolled or significant cardiovascular disease
  • Known connective tissue disease such as Marfan, Ehlers-Danlos, or Loeys-Dietz syndrome
  • Medical requirement for chronic anticoagulant or antiplatelet agents (except low-dose aspirin, which is permitted)

Other protocol-defined inclusion/exclusion criteria apply


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04943900


Contacts
Layout table for location contacts
Contact: Recruiting sites have contact information, Please contact the sites directly. If there is no contact information, please email: Clinical.Trials@bms.com
Contact: First line of email MUST contain NCT # and Site #.

Locations
Layout table for location information
United States, Georgia
Local Institution
Atlanta, Georgia, United States, 30322
Contact: Site 0006         
United States, Maryland
Local Institution
Baltimore, Maryland, United States, 21231
Contact: Site 0005         
United States, New Jersey
Local Institution
Hackensack, New Jersey, United States, 07601
Contact: Site 0002         
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States, 15232
Contact: Site 0003         
United States, Texas
Local Institution
Houston, Texas, United States, 77030
Contact: Site 0004         
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada, T6G 1Z2
Contact: Site 0009         
Canada, Ontario
Local Institution
Toronto, Ontario, Canada, M5G 1Z5
Contact: Site 0008         
Canada, Quebec
Local Institution
Montréal, Quebec, Canada, H2X 3E4
Contact: Site 0001         
Sponsors and Collaborators
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Additional Information:
Layout table for additonal information
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT04943900    
Other Study ID Numbers: CA102-003
First Posted: June 29, 2021    Key Record Dates
Last Update Posted: June 29, 2021
Last Verified: June 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bristol-Myers Squibb:
BMS-986416
Nivolumab
Opdivo
Non-small cell lung cancer (NSCLC)
Urothelial carcinoma (UC)
Squamous cell carcinoma of the head and neck (SCCHN)
Hepatocellular carcinoma (HCC)
Microsatellite-stable colorectal carcinoma (MSS CRC)
Pancreatic ductal adenocarcinoma (PDAC)
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action